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OBJECTIVES: To evaluate the inﬂuence of inadequate metabolic
control (IC) in comorbidities and the utilization of resources of
patients with diabetes mellitus attended at primary care setting
(PCS)in daily practise. METHODS: A retrospective-multicenter
population-based study was carried out, involving outpatient
records (>30 years) managed at seven PCS during year-
2006. NCEP-ATP III recommendations were followed, IC:
HbA1c > 7%. The control-group was formed with patients
without ICs. Main outcomes measures were comorbidity (hyper-
tension, hypercholesterolemia, smoking, obesity, cardiovascular
events [CVE], COPD, depression, microvascular complications,
etc.), as determined by Charlson-index (severity), clinical param-
eters (BMI, total-cholesterol, LDL-cholesterol, HDL-cholesterol,
glucose, triglycerides), resources utilization (specialist referrals,
medical visits, drugs, diagnostic tests) and corresponding costs.
Descriptive statistics, logistic regression model and analysis of
covariance (ANCOVA) with Bonferroni correction were applied,
using SPSSWIN v-12.0 and a statistical signiﬁcance of p < 0.05.
RESULTS: A total of 5277 patients (age: 67.1  12.0 years,
women: 49.7%) were included in the analysis. 30.4% had IC
(CI95%: 29.2–31.6%) and 25.0% (CI95%: 23.8–26.2%) suf-
fered a CVE. Patients with IC: Charlson-index 1.2  0.4 vs.
1.1  0.5 and CVE 0.4  0.7 vs. 0.3  0.7, p < 0.0001. Logistic
regression showed the association between IC and the existence
of a stroke (OR = 1.3, CI95%: 1.1–1.6), smoking (OR = 1.4,
CI95%: 1.2–1.6) and retinopathy (OR = 1.5, CI95%: 1.2–1.8),
p < 0.001). Clinical parameters in patients with/without IC,
respectively: BMI 30.5  5.5 vs. 29.9  4.9 kg/m2, glucose
176.4  59.0 mg/dl vs. 128.1  30.9 mg/dl, triglycerides
175.0  150.4 vs. 143.2  91.7, total-cholesterol 195.5  44.2
vs. 189.4  38.2, LDL-c 110.0  37.2 vs. 106.8  33.8 mg/dl
(p < 0.002). Total cost/patient/year adjusted (age-sex, morbidity)
was: €1612.18 (CI95%: €1490.48–1733.88) vs. €1937.49
(CI95%: €1829.53–2045.45), pharmaceutical cost represents a
71.5% (€1151.10–1437.91), p = 0.001. CONCLUSION: IC in
patients with diabetes mellitus is prevalent and it is associated
with smoking, stroke and retinopathy. Therapeutic goals have a
worse proﬁle in these patients, despite of taking more medicines.
GPC should promote speciﬁc interventions in this group of
patients.
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OBJECTIVES: To validate the external validity of 2 randomized
controlled trials (RCTs) through using large national observa-
tional studies that used electronic medical records and causal
effect methods, such as propensity score (PSM), marginal struc-
ture model (MSM) and doubly robust methods (DRM).
METHODS: The results of 2 RCTs (n = 105 and 97; crossover at
16th weeks) were validated using national observational studies
with causal estimation methods (OSCEM) studies (n = 4,519,
in 4 post-baseline quarters). The common outcomes were the
differences of treatment effect between 2 insulin regimens.
The treatment effect was deﬁned as the reduction of hemoglo-
bin A1c (HbA1c) among patients with type 2 diabetes. The 2
insulin regimens were once-daily basal analog insulin
(QDBAI)—glargine vs. twice-daily premixed analog insulin
(BIDMAI)—lispro mix 75/25. The causal estimation methods
include propensity score, marginal structural model and doubly
robust methods. RESULTS: The differences of HbA1c reductions
between BIDMAI and QDBAI in 4 quarters estimated through
2 RCTs were similar to the differences estimated through
3 OSCEMs (RCTs: -0.39—p = 0.02, -0.38—p = 0.03 vs.
OSCEMs: -0.48—p < 0.01, -0.72—p = 0.12, -0.31—p = 0.11)
CONCLUSION: Our large national OSCEMs results converge
with 2 RCTs in regards to the cross-regimen difference of treat-
ment effects. This may indicate a good external validity of 2
RCTs. OSCEMs are larger sample methods that may have better
external validity, but require a large sample size. Compared to
PSM, MSM and DRM are less efﬁcient, may require an even
larger sample size.
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OBJECTIVES: To estimate the long-term clinical outcomes in
type 1 diabetes patients treated with either insulin detemir (IDet)
or neutral protamine Hagedorn (NPH) insulin based basal-bolus
therapy in a Spanish setting. METHODS: A validated computer
simulation model of type 1 diabetes (the CORE Diabetes Model)
was used to make long-term projections of clinical outcomes
based on patient characteristics (mean age 40.3 years, duration
of diabetes 16.3 years, HbA1c 8.3%, BMI 25.2 kg.m-2) and
treatment effects (HbA1c improvement of 0.13% points, a 4%
decrease in hypoglycaemic events and lower body mass index of
0.21 kg.m-2 with IDet) from a ﬁxed-effects meta-analysis of
three clinical trials (n = 1555) where patients received either
NPH or IDet as the basal component of therapy. Clinical out-
comes were discounted at 3.5% per annum. RESULTS: IDet was
projected to improve discounted life expectancy by approxi-
mately 0.082 years (14.42  0.17 versus 14.33  0.17 years)
and quality-adjusted life expectancy by 0.173 quality-adjusted
life years (QALY) (7.21  0.09 versus 7.04  0.08 QALYs) com-
pared to NPH. The mean time to onset of any diabetes-related
complication was delayed by 0.07 years in the IDet arm (1.11
versus 1.04 years) with the cumulative incidence (CI) of diabetes
related complications over the patient lifetimes reduced. For
example, the CI of end stage renal disease (ESRD) was 2.4%
lower (18.3% versus 18.8%) with IDet versus NPH and, simi-
larly, beneﬁts were projected for proliferative diabetic retinopa-
thy (4.4% lower, 21.7% versus 22.7%) and peripheral vascular
disease (2.7% lower, 14.4% versus 14.8%). CONCLUSION:
The use of IDet versus NPH was projected to lead to reduced
complication costs over patient lifetimes, particularly for ESRD
and retinopathy, due to improvements in glycaemic control. This
is despite the survival paradox whereby IDet patients live longer
than those receiving NPH and are therefore at a greater risk of
complications.
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